Company Profile
uniQure N.V. Stock Price, News & Catalysts
- Ticker:
- QURE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands
Stock performance
23.06 USD (+1.14%)
Close
Last updated: October 6, 2026
1.69B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, QURE closed up 1.14% at $23.06. No new same-company headline was identified in the current news window.
Company overview
AAV Gene Therapy Company
uniQure develops adeno-associated virus gene therapies intended to provide durable benefit after a single administration. The company combines vector engineering, manufacturing, neurosurgical delivery, clinical development, and regulatory expertise across severe neurological and genetic diseases.
Huntington's Disease Program
AMT-130 is an investigational gene therapy designed to lower mutant huntingtin protein in the brain. It is uniQure's lead program and is being advanced toward regulatory submissions based on clinical follow-up from treated patients and an accelerated-approval strategy in the United States.
Neurological Pipeline
AMT-260 is being developed for refractory mesial temporal lobe epilepsy using targeted delivery to brain regions involved in seizure generation. The broader neurological portfolio also includes AMT-162 for SOD1 amyotrophic lateral sclerosis and additional programs that apply the company's CNS delivery capabilities.
Rare-Disease Gene Therapy
AMT-191 is an investigational gene therapy for Fabry disease designed to generate sustained alpha-galactosidase A activity. uniQure also retains economic and manufacturing exposure to HEMGENIX, the hemophilia B gene therapy originally developed by the company and commercialized by CSL Behring.
Future catalysts
- U.S. BLA submission for AMT-130 under the accelerated-approval pathway in the third quarter of 2026.
- U.K. regulatory submission for AMT-130 in the third quarter of 2026.
- Presentation of four-year Phase 1/2 AMT-130 data in September 2026.
- Completion of enrollment in the second AMT-260 dose cohort in the third quarter of 2026.
- Updated Phase 1/2a AMT-260 results in refractory mesial temporal lobe epilepsy in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of uniQure N.V. (QURE)?
uniQure N.V. (QURE) most recently closed at 23.06 USD, a +1.14% move versus the previous session.
What is the market cap of uniQure N.V. (QURE)?
uniQure N.V. currently has a market capitalization of 1.69B USD on BioPharmSignal.
What does uniQure N.V. do?
AAV Gene Therapy Company uniQure develops adeno-associated virus gene therapies intended to provide durable benefit after a single administration. The company combines vector engineering, manufacturing, neurosurgical delivery, clinical development, and regulatory expertise across severe neurological and genetic diseases. Huntington's Disease Program AMT-130...
On which exchange is QURE stock listed?
uniQure N.V. (QURE) is associated with NASDAQ, Netherlands, Biopharma.
What is AMT-130?
BLA submission for AMT-130 under the accelerated-approval pathway in the third quarter of 2026.
Which conditions is uniQure N.V. targeting with AMT-130?
uniQure N.V. is associated with genetic disease based on its company overview and current catalyst commentary.
How does uniQure N.V. describe recent progress with AMT-130?
BLA submission for AMT-130 under the accelerated-approval pathway in the third quarter of 2026.
What is AMT-260?
Neurological Pipeline AMT-260 is being developed for refractory mesial temporal lobe epilepsy using targeted delivery to brain regions involved in seizure generation.